EMA601 News
Latest articles and news about EMA601 on AXL Media.
Latest Articles
- Boehringer Ingelheim Partners With EMFRET Analytics To Advance EMA601 As First-In-Class Thrombo-Inflammatory Stroke Treatment
Published: Mar 31, 2026
Section: Research
Pharmaceutical giant Boehringer Ingelheim has entered a strategic licensing agreement to develop EMA601, a novel antibody targeting the GPVI receptor to treat acute stroke. Develop...
- Boehringer Ingelheim Partners with EMFRET Analytics to Develop First-in-Class Antibody Targeting Stroke Induced Brain Inflammation
Published: Mar 31, 2026
Section: Research
Boehringer Ingelheim and the Würzburg-based biotech firm EMFRET Analytics have entered a licensing agreement to advance EMA601, a novel antibody for acute stroke treatment. The the...